Proprietary drug names meeting
This article was originally published in The Tan Sheet
Executive SummaryPublic meeting on "Minimizing Medication Errors - Methods for Evaluating Proprietary Names for Their Confusion Potential" will be held June 26 by FDA, PhRMA, Institute for Safe Medication Practices (ISMP), according to 1May 30 Federal Register notice. Goal of meeting is to solicit views on FDA recommendation that drug manufacturers "perform proprietary name testing prior to submitting NDAs and ANDAs," agency says. Input from workshop, other comments "may be considered in developing a draft guidance on this topic," FDA adds...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.